[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zaid et al., 2017 - Google Patents

14 Thymoma and Thymic Carcinoma

Zaid et al., 2017

Document ID
9589660285482881255
Author
Zaid M
Kesler K
Smith J
Badve S
Sr P
Publication year
Publication venue
Textbook of Uncommon Cancer

External Links

Snippet

Soft tissue sarcomas are uncommon tumors, with an estimated incidence of approximately 11,930 cases and 4870 deaths in the USA in 2015.1 Sarcomas are derived from mesenchymal tissues and are therefore a diverse group of cancers. Three‐fourths of all soft …
Continue reading at books.google.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Zhu et al. Progress and challenges of immunotherapy in triple-negative breast cancer
Cohen‐Gogo et al. Ewing‐like sarcomas with BCOR‐CCNB3 fusion transcript: a clinical, radiological and pathological retrospective study from the Societe Francaise des Cancers de L'Enfant
Wright Management of thymomas
Ferreri et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Lamarca et al. Appendiceal goblet cell carcinoids: management considerations from a reference peritoneal tumour service centre and ENETS centre of excellence
JP7564122B2 (en) Methods and associated biomarkers for photoimmunotherapy - Patent Application 20070123633
US8586043B2 (en) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
Klimm et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
Wright et al. Surgical treatment of thymic tumors
Fan et al. Concomitant EGFR mutation and EML4-ALK rearrangement in lung adenocarcinoma is more frequent in multifocal lesions
Yüksel et al. 99m Tc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis
Gwin et al. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER−, PR−, Her2/neu−) cases
Zaid et al. 14 Thymoma and Thymic Carcinoma
Abu Zaid et al. Thymoma and Thymic Carcinoma
Loehrer Sr et al. Thymoma and thymic carcinoma
Moore et al. Thymoma and thymic carcinoma
Board Rare Cancers of Childhood Treatment (PDQ®)
Ravi et al. Primary Sarcomas of the Lung
Flieder et al. Adenocarcinoma of the lung
Marino et al. Thymic Neoplasm
Tayyar et al. The Relationship Between HER2 Status Acquired From Pathological Data and Metabolic Parameters From Pre-treatment 18F-FDG PET/CT in Gastric Adenocarcinomas
Thymus et al. Radiological Aspects of the Mediastinum The mediastinum contains vascular and nonvascular struc-tures, which can be involved in a wide variety of neoplastic, nonneoplastic, vascular, congenital, and lymphatic pro-cesses. Radiological imaging plays a central role in the eval
Cai et al. Thymic Epithelial Tumor
Baptista et al. 34th European Congress of Pathology-Abstracts
Gu Tumor-infiltrating lymphocytes as biomarkers to monitor local ablation of primary and secondary liver cancer